Primary objective:
To evaluate the impact of 12 weeks' administration of extended release niacin/laropiprant
(ERN/LRPT) compared to placebo added to statin therapy on endothelial dependant dilatation of
the arterial wall assessed by brachial vasoreactivity in stable coronary heart disease (CHD)
patients.
Secondary objective:
To evaluate the impact of 12 weeks' administration of extended release niacin/laropiprant
(ERN/LRPT) compared to placebo added to statin therapy on serum lipids and the parameters of
inflammation in stable coronary heart disease (CHD) patients.
CHD-coronary heart disease ER-extended release